Remember meForgot password?
    Log in with Twitter
| Press Release

Blog Exposure - Zimmer Biomet Showcased New Product and Service Innovations at American Academy of Orthopaedic Surgeons Annual Meeting 2018

Stock Monitor: GenMark Diagnostics Post Earnings Reporting

LONDON, UK / ACCESSWIRE / March 08, 2018 / has just released a free research report on Zimmer Biomet Holdings, Inc. (NYSE: ZBH). If you want access to this report all you need to do is sign up now by clicking the following link as the Company's latest news hit the wire. On March 06, 2018, the Company announced that it plans to highlight its latest commercial offerings and preview its next generation of technological innovations at the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting, between March 06-10 in New Orleans, Louisiana. Register today and get access to over 1,000 Free Research Reports by joining our site below: is currently working on the research report for GenMark Diagnostics, Inc. (NASDAQ: GNMK), which also belongs to the Healthcare sector as the Company Zimmer Biomet Holdings. Do not miss out and become a member today for free to access this upcoming report at: is focused on giving you timely information and the inside line on companies that matter to you. This morning, Zimmer Biomet Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

Zimmer Biomet's Latest Innovations

The key highlights being featured by the Company at the AAOS 2018 include:

  • Knees: Persona® Partial Knee System, Persona® Primary Knee System Micro Sizes, Persona® Trabecular Metal™ Tibia, and OSS™ Orthopedic Salvage System;

  • Biologics: nSTRIDE® APS Kit (ex-US use only);

  • Bone Cement: The US launch of Biomet and Refobacin® Bone Cement R offerings;

  • Diagnostics: Synovasure® comprehensive diagnostic panel for periprosthetic and native joint infection;

  • Extremities: Comprehensive® Augmented Baseplate and Newly FDA-Cleared Sidus® Stem-Free Shoulder;

  • Foot & Ankle: The Nextra® Hammertoe Correction System, the MSP™ Metatarsal Shortening System, Arcus® Staple System and the Re+Line® Bunion Correction System, and Subchondroplasty® Procedure for foot and ankle surgery;

  • Hips: Hip Preservation portfolio, G7® and Continuum® acetabular shells, Echo® Bi-Metric® Microplasty® hip stem, and Trabecular Metal™ acetabular shells;

  • Personalized Solutions: Comprehensive technology-based portfolio of guides, tools and software and X-PSI™ X-ray Patient Specific Instruments;

  • Robotic Technology: Follow the progress of the ROSA® Total Knee, including imaging, workflow, soft tissue adjustment and data collectioniii.

Zimmer Biomet Signature Solutions

The Company's Signature Solutions' unique platform creates value and savings for providers by offering a suite of products and solutions that strive to increase value, improve patient outcomes, and deliver cost-effective care. These are as follows:

  • Spine: Mobi-C® Cervical Disc and Vitality® Spinal Fixation System;

  • Sports Medicine: Quattro® Link, BioWick™ X, TCP Anchors, Gel-One® Cross-Linked Hyaluronate, and VISCO-3™ Sodium Hyaluronate;

  • Surgical: IntelliCart® System Duo Fluid Carts, Bactisure™ Wound Lavage, and ActiveCare® + S.F.T. System;

  • Trauma: FastFrame™ External Fixation System and THP™ Hip Fracture Plating System;

The Company will also host education and special presentations during the event.

Zimmer Biomet's Rapid Recovery Program Marked Two Decades of Success in Europe

On February 08, 2018, the Company marked the 20th anniversary of Rapid Recovery, an evidence-based program optimizing all aspects of a patient's care pathway and surgical experience. Zimmer Biomet pioneered Rapid Recovery in 1997 to complement its commercial product offerings and help healthcare providers improve the quality and cost-efficiency of patient care. The Company's Rapid Recovery program combines the principles of fast-track surgery with evidence-based approaches to process optimization, clinical enhancements, patient engagement, data collection and evaluation, strategy and marketing. To date, Zimmer Biomet has implemented the Rapid Recovery program in approximately 250 hospitals throughout Europe.

About Zimmer Biomet Holdings, Inc.

Founded in 1927 and headquartered is in Warsaw, Indiana, Zimmer Biomet is the world's most trusted brand for personalized bone and joint healthcare solutions. As a leading innovator in musculoskeletal healthcare, the Company offers a complete portfolio of products for joint reconstruction, bone, and skeletal repair, sports medicine, spine, and dental reconstruction.

Stock Performance Snapshot

March 07, 2018 - At Wednesday's closing bell, Zimmer Biomet's stock rose 2.46%, ending the trading session at $121.00.

Volume traded for the day: 1.35 million shares.

Stock performance in the last three-month – up 5.38%; previous six-month period – up 5.92%; past twelve-month period – up 3.36%; and year-to-date - up 0.27%

After yesterday's close, Zimmer Biomet's market cap was at $24.50 billion.

Price to Earnings (P/E) ratio was at 13.60.

The stock has a dividend yield of 0.79%.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.5% at the end of the session.


Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:


Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

Latest News
Top News